Janux Therapeutics (NASDAQ:JANX) just lit up the biotech world with staggering results from its Phase 1a trial of JANX007, its cutting-edge therapy for metastatic castration-resistant prostate cancer (mCRPC). The drug didn't just performit overdelivered. All 16 patients saw at least a 50% drop in PSA levels, a key cancer marker, with 63% hitting a PSA90 reduction and 31% achieving a mind-blowing PSA99 drop. Analysts are buzzing, calling the results unprecedented, and Janux stock didn't miss a beat, surging 69% this morning. That's on top of a jaw-dropping 650% climb over the past year.
Safety? Check. JANX007 was well-tolerated, with mostly mild side effects (grades 1 and 2) and nothing alarming cropping up during the trial. The company's rock-solid financials, with near-zero debtmean they've got the cash runway to push forward aggressively. Next up? Expansion trials for patients on second- and third-line therapies who haven't tried Pluvicto. UBS and Leerink Partners have already bumped their price targets to $69 and $79, respectively, as analysts adjust their sales forecasts upwardsome now seeing JANX007 hitting $3 billion in peak U.S. sales.
But this isn't just about one drug. Janux's broader TRACTr platform is shaping up to be a game-changer in oncology, and the company is hosting a virtual event today to dive deeper into its plans. CEO David Campbell is eyeing a huge opportunity to dominate in areas with major unmet needs. For investors, this could be a defining moment. Janux isn't just riding a waveit's leading one, and Wall Street is taking notice.
This article first appeared on GuruFocus.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.